Ind-Swift Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+14.2%−19.0%
EBITDA—−41.8%
Net Income−83.5%−4.5%
EPS (adj.)−83.5%−4.5%
Total Assets+16.4%−2.8%
Total Equity+18.0%+26.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDSWFTLAB₹378.95

Ind-Swift Laboratories Limited

· Pharma & Health
₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,291 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+14.2-19.0
EBITDA—-41.8
Net Income-83.5-4.5
EPS (adj.)-83.5-4.5
Total Assets+16.4-2.8
Total Equity+18.0+26.6
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.